Health Economics
Primary health economic analysis is based on cost-effectiveness for readmissions within 90 days. If CHARMER is both less expensive and more effective than usual care, it is considered to dominate usual care. The economic evaluation is cond…
1 sources - 6 claims
Primary health economic analysis is based on cost-effectiveness for readmissions within 90 days. If CHARMER is both less expensive and more effective than usual care, it is considered to dominate usual care. The economic evaluation is conducted from the NHS perspective. The consented subsample provides EQ-5D-5L quality-of-life data at baseline and 90 days post-discharge. A long-term health economic model will explore longer-term prescribing costs and mortality. The evaluation includes resources needed to deliver CHARMER, including workshops, video viewing, briefings, action-plan preparation, and benchmarking reports.